FeRX tests MTC (Magnetic Targeted Carrier)-based gene therapy in Japan:
This article was originally published in Clinica
FeRx has entered into a research agreement with Japan's National Cancer Center Research Institute (NCCRI) to develop a tumour-targeting gene transfer approach that uses FeRx's Magnetic Targeted Carrier (MTC) drug delivery technology. "An important goal of the collaboration will be improvement of the site specific delivery of genetic vectors to the disease site, one of the continuing development challenges facing gene therapy," said Dr Takahiro Ochiya of the NCCRI. MTC uses magnetic fields to target agents to specific areas in the body. The San Diego, California firm is already testing the method in the treatment of cancers (see Clinica No 1010, p 24).